Personalized Medicine – News and Features

Researchers have developed new AI models that can vastly improve accuracy and discovery within protein science. Potentially, the models will assist the medical sciences in overcoming present challenges within personalized medicine and drug discovery.

A novel PET imaging method successfully quantifies COX-2 enzyme levels in the human brain. This technique opens the door for earlier detection, monitoring of disease progression, and evaluating anti-inflammatory treatments for brain disorders.

The complexity of the TME in vivo limits the conclusions that can be drawn from in vivo models. Optimizing cell culture models to mimic the TME is vital to understanding cancer progression and the development of optimized therapies.

A breakthrough in safely delivering therapeutic DNA to cells using lipid nanoparticles could transform treatment for millions suffering from common chronic diseases like heart disease, diabetes, and cancer.

We spoke with Dr. Michael Gonzales to learn more about the UKB-PPP and its goals, the technical hurdles of large-scale proteomics and how Olink technology is helping to overcome them.

The DYNA AI model from Cedars-Sinai identifies harmful genetic mutations linked to diseases, including cardiovascular conditions. Unlike existing models, DYNA connects specific gene variants to diseases, improving diagnosis accuracy.

New research, in a rat model, finds that both biological sex and mitochondrial DNA – the small set of genes inherited only from mothers – play a key role in how gut bacteria change over time.

The new method can measure 25 important markers in the blood simultaneously, such as cholesterol, in less than 15 minutes using radio waves. This new application could support more patients achieve an early heart disease diagnosis.

A first-of-its-kind artificial intelligence-based neural network can rapidly analyze and interpret millions of cells from a patient sample, predicting molecular changes in the tissue.

Researchers uncover new insights into the molecular mechanisms of ADAR1, a protein that regulates RNA-induced immune responses. Their findings could open new pathways for treating autoimmune diseases and enhancing cancer immunotherapy.